Program
Octreotide Sustained-release Formulation Debio 4126
Its studies are mostly in Acromegaly, led by Debiopharm.
Furthest: phase 3, since Apr 9, 20252 company-led studies, 1 open or runningNext primary completion: Jun 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Debiopharm | 21 open or running | phase 3since Apr 9, 2025 | May 4, 2022 | Jun 2028phase 3 · NCT06930625 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 4, 2022First study: phase 1 study in AcromegalyFirst studyNCT05364944 · 19 enrolled · Denmark, France, Germany and more
- Apr 9, 2025Phase 3 study in AcromegalyNCT06930625 · 119 planned · United States, Austria, Belgium and more
Ahead
- Jun 2028Primary completion: phase 3 study in AcromegalyNCT06930625
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06930625Acromegaly · United States, Austria, Belgium and more | 3 | Recruiting | Jun 2028 | 119 |
| NCT05364944Acromegaly · Denmark, France, Germany and more | 1 | Terminated | Oct 29, 2024 | 19 |
How it is read
Names in the registry
- “Debio 4126”, 2 entries
Conditions, from the studies’ own filings
- Acromegaly, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.